Minimal Residual Disease Status as a Surrogate Endpoint ...
Recent advances in multiple myeloma treatment, including proteasome inhibitors, immunomodulators, and antibody therapies, have significantly improved patient prognosis, with overall response rates nearing 100%. The use of minimal residual disease (MRD) status as a surrogate endpoint in clinical trials is being explored, with studies showing MRD-negative responses correlate with superior survival outcomes. The FDA and Duke-Margolis Center for Health Policy have discussed MRD's potential as a surrogate endpoint, emphasizing the need for it to meet specific criteria to predict clinical benefit effectively.
Reference News
Recent advances in multiple myeloma treatment, including proteasome inhibitors, immunomodulators, and antibody therapies, have significantly improved patient prognosis, with overall response rates nearing 100%. The use of minimal residual disease (MRD) status as a surrogate endpoint in clinical trials is being explored, with studies showing MRD-negative responses correlate with superior survival outcomes. The FDA and Duke-Margolis Center for Health Policy have discussed MRD's potential as a surrogate endpoint, emphasizing the need for it to meet specific criteria to predict clinical benefit effectively.